AbbVie exploits U.S. patents to protect profits: Congress report – Reuters

AbbVie exploits U.S. patents to protect profits: Congress report – Reuters

Drugmaker AbbVie (ABBV.N) exploits the U.S. patent system to push up prices for its Humira rheumatoid arthritis drug and Imbruvica, a cancer drug, according to a U.S. House of Representatives Oversight Committee staff report issued on Tuesday.

Read More…

You May Also Like